Safety with the senhance™ robotic system in 3,239 patients across various surgical disciplines.

Abstract

Purpose: At present, robotic surgery has found its most frequent application in gastrointestinal, gynaecological, and urological procedures, presenting a seamless integration of advanced technology. The Senhance™ Robotic System certainly contributes to this evolution, gracefully employed to enhance precision and efficacy in these surgical disciplines. However, safety data, such as conversion rates, robotic malfunctions, and adverse event rates, are still lacking on a large scale.

Methods: To shed light on this, data from nine European centres (N = 3,239) was collected prospectively as part of the TRUST registry.

Results: Our results present most data from gastrointestinal surgery (2,132 cases), followed by procedures from gynaecology (609 cases) and urology (498 cases). Overall, we found a conversion rate of 4.5% (147 cases). Robotic malfunctions were seen in 3% (96 cases) of the procedures, with console malfunctions occurring in 0.5% (16 cases), monitor or camera issues affecting 0.5% (17 cases), and other malfunctions registered in 2.1% (69 cases). The most common robotic limitations were displayed by limited motion (15.6%, 505 cases) and collisions (6.2%, 202 cases). Finally, we found a 3.9% rate of adverse events, with 127 episodes across all three disciplines. Most adverse events were judged as mild in severity (53 cases) and unrelated (101 cases) to the robotic system. Additionally, only one case was considered to be certainly related to the Senhance™ Robotic System, and just three serious adverse events occurred intraoperatively.

Conclusion: In conclusion, our data demonstrates that performing gastrointestinal, gynaecological, and urological surgeries with the Senhance™ Robotic System can be safe for patients and surgeons.